Oligonucleotides - Competitive landscape and Clinical Trial Analysis, 2026

DelveInsight’s, “Oligonucleotides - Competitive landscape and Clinical Trial Analysis, 2026,” report provides comprehensive insights about 200+ companies and 600+ drugs in Oligonucleotides Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, therapy area and molecule type, clinical trial assessment by phase, status, sponsor and geography etc. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Oligonucleotides: Understanding

Oligonucleotides: Overview

Oligonucleotides are short nucleic acid polymers (typically 13–25 nucleotides) composed of a sugar, nitrogenous base, and phosphate backbone, with the unique ability to bind complementary DNA or RNA via Watson–Crick base pairing. This specificity enables their use as both molecular probes and therapeutics, regulating gene expression through mechanisms such as RNA interference, RNase H-mediated degradation, splicing modulation, non-coding RNA inhibition, gene activation, and genome editing. They are categorized into antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNAs), and aptamers, and are being explored across indications including neurodegenerative disorders, cancer, orphan diseases, and other conditions, with several in clinical trials. Upon administration, they distribute widely across tissues, particularly accumulating in the liver, kidney, and immune-related cells, and are metabolized by nucleases rather than cytochrome P450 enzymes, followed by renal or hepatic excretion. While oral delivery was previously limited, advances with absorption enhancers have improved bioavailability. Their high sequence specificity allows precise targeting of disease-causing genes with minimal off-target effects, making them promising candidates for treating conditions associated with traditionally undruggable targets, as well as for applications in diagnostics and gene therapy.

Oligonucleotides are short chains of nucleotides, key building blocks of nucleic acids, typically ranging from a few units up to ~20 nucleotides, though broader definitions extend to 100–200, and they play a vital role in molecular biology, biotechnology, and therapeutics due to their ability to selectively hybridize with complementary nucleic acid sequences. Each nucleotide comprises a five-carbon sugar (deoxyribose in DNA or ribose in RNA), a phosphate group, and a nitrogenous base (A, T, C, G in DNA, with U replacing T in RNA), where the precise base sequence determines identity, specificity, and function in applications such as PCR, sequencing, gene editing, and antisense therapy, while the sugar-phosphate backbone provides structural stability. This backbone consists of repeating sugar and phosphate units linked by phosphodiester bonds, creating a negatively charged framework that influences solubility, molecular interactions, and analytical behavior, with a defined 5? to 3? directionality essential for synthesis and function. Structurally, oligonucleotides may exist as single- or double-stranded molecules, with complementary strands forming stable helices through Watson–Crick base pairing (A–T/U and G–C), where DNA typically adopts a B-form helix and RNA an A-form helix, each differing in compactness and groove structure, thereby affecting biological interactions; additionally, sequence-dependent folding into secondary structures such as hairpins and G-quadruplexes further expands their functional versatility.

Oligonucleotides, short DNA or RNA molecules, are categorized by function into antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), microRNAs (miRNAs), aptamers, CpG oligonucleotides, and decoys, each serving distinct roles in gene modulation and therapy. ASOs (~12–30 nt) bind target RNA and often require backbone modifications (e.g., phosphorothioate, methylphosphonate) to enhance stability, cellular uptake, and circulation, with phosphorothioate ASOs uniquely retaining RNase H-mediated degradation activity, as seen with fomivirsen. miRNAs (~18–25 nt) are endogenous regulators of gene expression via the RISC complex and are implicated in cancer and drug resistance, while siRNAs (20–25 bp) similarly mediate RNA interference and rely on chemical modifications and nanoparticle delivery for improved stability and targeting. Aptamers are structurally complex oligonucleotides selected via SELEX that bind targets with high specificity, enabling applications in drug delivery, immune modulation, and diagnostics, though they require modifications for stability. CpG oligonucleotides activate immune responses through Toll-like receptor 9, with different structural classes inducing varied immunological effects. Decoy oligonucleotides act by binding transcription factors and preventing gene activation, offering a therapeutic strategy currently under clinical investigation for autoimmune and inflammatory diseases.

Oligonucleotides modulate gene expression through sequence-specific interactions with target nucleic acids or proteins, enabling precise therapeutic effects. Antisense oligonucleotides (ASOs) bind complementary mRNA and act via two key mechanisms: steric blockade, which inhibits translation or splicing, and RNase H-mediated cleavage, which degrades mRNA and significantly reduces protein expression, offering flexible targeting across coding regions. Small interfering RNAs (siRNAs) function through the RNA interference pathway by guiding the RNA-induced silencing complex (RISC) to cleave target mRNA, while microRNA (miRNA)-based approaches either mimic or inhibit endogenous miRNAs to regulate gene expression. Aptamers, structured single-stranded oligonucleotides, bind proteins with high specificity, similar to antibodies. Overall, oligonucleotide therapies act through RNA cleavage or RNA blockage mechanisms, with chemical modifications enhancing stability, delivery, and efficacy, ultimately enabling either suppression of disease-causing proteins or restoration of normal protein function.

Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and splice-switching oligonucleotides, hold significant potential for treating genetic and acquired diseases, but their success depends on overcoming delivery challenges such as large size, negative charge, nuclease degradation, limited tissue penetration, and rapid clearance. To address these barriers, delivery strategies like lipid nanoparticles (LNPs) and polymeric nanoparticles enhance stability, uptake, and controlled release, though concerns around immunogenicity and complexity remain, while biologically derived carriers such as exosomes offer high biocompatibility but face scalability issues. Bioconjugate approaches, including antibody- and peptide-based systems, improve targeting and cellular uptake, although endosomal escape remains a key limitation. Direct delivery routes (e.g., intravitreal, intrathecal) enable localized treatment, whereas systemic administration is more practical but less specific. Ligand-based targeting, such as GalNAc conjugation for liver delivery, has shown strong efficacy, though extrahepatic targeting remains challenging, highlighting the need to balance stability, specificity, and scalability across delivery platforms.

Oligonucleotides have emerged as powerful tools in both diagnostics and therapeutics due to their high specificity, programmability, and ease of synthesis. In diagnostics, they serve as precise and cost-effective alternatives to antibodies, with applications in PCR and qPCR for amplifying and quantifying target nucleic acids in conditions such as viral infections and cancer, as well as in sequencing and hybridization-based techniques like Southern blotting, Northern blotting, and fluorescence in situ hybridization (FISH). High-throughput platforms such as microarrays and CRISPR-based diagnostics further leverage oligonucleotides for large-scale mutation detection and rapid disease identification, while aptamer-based imaging enables targeted visualization of biomarkers, supported by chemical modifications that enhance stability and binding affinity. Therapeutically, oligonucleotides are increasingly used to modulate gene and protein function, with aptamers acting as antibody-like ligands, and antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) enabling targeted gene silencing, as demonstrated in treatments for genetic disorders and amyloidosis. MicroRNA modulators and CRISPR-Cas9 systems further expand their role in gene regulation and editing, while nucleic acid-based vaccines, including mRNA and DNA platforms, have revolutionized rapid vaccine development. Additional innovations such as CpG oligonucleotides for immunotherapy and antidote oligonucleotides highlight their expanding clinical scope. Despite challenges such as off-target effects, rapid clearance, and toxicity, advancements in conjugation strategies and delivery technologies continue to enhance their precision, safety, and therapeutic potential, positioning oligonucleotides at the forefront of precision medicine.

Report Highlights

• In December 2025, SanegeneBio announced the closing of Series B financing round, raising over USD 110 million. The financing will advance its clinical stage assets towards registrational studies and accelerate the development of programs across several therapeutic areas, powered by its industry-leading RNAi technologies including the LEAD™ (Ligand and Enhancer Assisted Delivery) delivery platform.
• In December 2025, Praxis Precision Medicines, Inc., announced the completion of a Type C meeting with the U.S. Food and Drug Administration (FDA) and agreement to immediately convert the EMBRAVE3 registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy (DEE) into a single-arm study where all patients will receive elsunersen for 24 weeks, followed by an open-label extension.
• In December 2025, Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).
• In November 2025, PepGen Inc. announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new composition of matter patent covering PGN-EDODM1, which leverages PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform, including its unique peptide and linker chemistry. This newly issued composition of matter patent is expected to provide exclusivity for PGN-EDODM1 in the United States into second half of 2042, with the possibility of patent term extension following FDA approval of PGN-EDODM1.
• In October 2025, Nippon Shinyaku Co., Ltd. announced the efficacy and safety data of 3.5 years of administration based on an open-label extension study, including an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02).
• In October 2025, SanegeneBio announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SGB-9768 for the treatment of C3 Glomerulopathy (C3G).
• In October 2025, ADARx Pharmaceuticals, Inc. announced that the first patient has been dosed in its Phase III STOP-HAE clinical trial evaluating ADX-324 in patients with hereditary angioedema (HAE). Additionally, ADARx announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADX-324 for the treatment of patients with HAE.
• In October 2025, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for the treatment of Hepatitis D Virus (HDV) infection.
• In September 2025, Argo Biopharmaceutical Co., Ltd. announced that the first patient dosing has been completed for the Phase II clinical trial of its innovative siRNA-based therapy in chronic hepatitis B (CHB) patients. The Phase II study will test both BW-20507 mono-therapy and combination therapy of BW-20507 and PEG-IFN?.
• In July 2025, Argo Biopharmaceutical Co., Ltd. announced that National Medical Products Administration of China (NMPA) has granted Investigational New Drug (IND) approval for Phase II clinical trial of its innovative siRNA-based therapy, BW-20507 to be combined with standard-of-care PEG-IFN? for the treatment of chronic hepatitis B (CHB, chronic HBV).
• In June 2025, Argo Biopharmaceutical Co., Ltd. announced that its investigational drug BW-20507 has been granted Breakthrough Therapy Designation (BTD) by China Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B (CHB, chronic HBV) infection. This recognition is based on the molecule’s demonstrated potent antiviral activity and favorable safety profile in early-stage clinical trials, positioning it as a potential transformative therapy for HBV patients.
• Sapablursen was granted Fast Track designation in January 2024 and orphan drug designation in August 2024 by the US Food and Drug Administration (FDA), along with Breakthrough Therapy designation in May 2025.
• In April 2025, Biogen Inc. announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease.
• In April 2025, Oak Hill Bio entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in- class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Oak Hill plans to initiate a Phase III study in early 2026.
• In March 2025, Wave also announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to discuss its interim 24-week data and initial plans for the confirmatory trial, where the Agency confirmed that the accelerated approval pathway using dystrophin expression as a surrogate endpoint remains open. Based on the FDA feedback and the 48-week data, Wave intends to file a New Drug Application (NDA) in 2026 for accelerated approval of WVE-N531. The NDA filing will be based on all FORWARD-53 data, which will include additional data to support monthly dosing. Furthermore, Wave will continue to engage the Agency with the new 48-week data, including functional outcomes, and its planned global confirmatory trial of WVE-N531.
• In March 2025, Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, announced that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata (AA), a chronic autoimmune disease with significant unmet medical need that often leads to significant psychological distress and a reduced quality of life.
• In March 2025, Rona Therapeutics Inc. announced the clearance of an Investigational New Drug (IND) by the US Food and Drug Administration (FDA) for RN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS) treatment. The company plans to advance RN0361 development in HTG patients based on a favorable safety profile and sustained triglyceride (TG) reduction in a 6-month single dose Phase I clinical trial.

Oligonucleotides: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Novartis

Novartis International AG is a Switzerland-based global healthcare leader and among the world’s largest pharmaceutical companies. Established in 1996 through the merger of Ciba-Geigy and Sandoz, the company operates across the research, development, manufacturing, and commercialization of a wide portfolio of healthcare products, including innovative pharmaceuticals, generics, and biosimilars. Novartis also emphasizes sustainable healthcare by pursuing initiatives aimed at reducing environmental impact and expanding access to medicines, particularly by improving affordability and availability in low- and middle-income countries.

Product Description: LEQVIO

Leqvio (inclisiran) is a first-in-class small interfering RNA (siRNA) therapy developed by Novartis International AG that targets PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA. Unlike conventional treatments, it inhibits the production of the PCSK9 protein in the liver, thereby enhancing hepatic uptake and clearance of LDL-C from the bloodstream. In 2023, Ministry of Health, Labour and Welfare approved inclisiran for both familial and non-familial hypercholesterolemia, as well as for patients at high cardiovascular risk. The therapy is administered as an initial dose, followed by a second injection at three months and maintenance doses every six months thereafter. Clinical studies have shown that, when used alongside statins, inclisiran can lower LDL-C levels by approximately 50%.

2. Company Overview: Astellas Pharma Inc.

Astellas Pharma Inc. is a Tokyo-based multinational pharmaceutical company formed in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co.. The company focuses on key therapeutic areas including oncology, urology, immunology, and neuroscience, with a strong emphasis on research and development to address unmet medical needs and improve patient outcomes. It also actively engages in global partnerships and collaborations to accelerate drug discovery and strengthen its presence across major markets such as North America, Europe, and Asia.

Product Description: IZERVAY

Izervay (avacincaptad pegol) is an approved therapy for geographic atrophy, designed as an RNA aptamer conjugated to a branched polyethylene glycol (PEG) molecule. It functions by inhibiting complement factor C5, a critical component of the inflammatory complement cascade associated with age-related macular degeneration, thereby preventing its cleavage into active fragments (C5a and C5b) to reduce inflammation and slow disease progression. The drug received approval from the U.S. Food and Drug Administration on August 4, 2023, for geographic atrophy secondary to AMD and is currently under review by the European Medicines Agency, while also being investigated for the treatment of Stargardt disease.

3. Company Overview: Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a Cambridge, Massachusetts–based biopharmaceutical company dedicated to the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Founded in 2002, it is a pioneer in RNAi technology, enabling targeted gene silencing to address disease at the molecular level. The company’s pipeline spans rare genetic, cardio-metabolic, and hepatic infectious diseases, supported by approved therapies such as Onpattro, Givlaari, Oxlumo, and Amvuttra. With a strong focus on innovation, strategic collaborations, and global expansion, Alnylam aims to transform treatment options for patients with limited therapeutic alternatives.

Product Description: AMVUTTRA

Amvuttra (vutrisiran) is an RNA interference (RNAi) therapeutic designed to rapidly reduce transthyretin (TTR) production, thereby targeting the root cause of transthyretin amyloidosis. Administered as a quarterly subcutaneous injection by a healthcare professional, it is approved in over 15 countries for treating polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR-PN). In the United States, it is also approved for adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), where it helps reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.

4. Company Overview: Ionis Pharmaceuticals

Ionis Pharmaceuticals Inc., founded in 1989 and headquartered in Carlsbad, California, is a biotechnology company focused on RNA-targeted therapeutics. A pioneer in antisense technology, it develops treatments for a wide range of conditions, including neurological, cardiovascular, and rare diseases, leveraging its proprietary platforms in antisense and RNA interference (RNAi). The company emphasizes precision medicine and collaborates with leading pharmaceutical partners to advance its pipeline, supported by a diversified portfolio of both wholly owned and partnered programs. Publicly traded on Nasdaq, Ionis continues to strengthen its position in the biopharmaceutical sector by driving innovation in RNA-based therapies.

Product Description: Tegsedi

Tegsedi (inotersen) is an antisense oligonucleotide therapy indicated for adults with hereditary transthyretin-mediated amyloidosis (hATTR) with stage 1 or 2 polyneuropathy, acting by reducing transthyretin (TTR) production to slow nerve damage progression. It is administered as a once-weekly 284 mg subcutaneous injection and is approved in the United States, Europe, Canada, and Brazil for ATTRv-PN. Due to potential serious adverse effects, including thrombocytopenia and renal inflammation, regular monitoring is required, and in the United States it is available only through the Tegsedi Risk Evaluation and Mitigation Strategy (REMS) Program to ensure safe use. Common side effects include injection site reactions, nausea, headache, fatigue, and fever.

Oligonucleotides: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Novartis

Novartis International AG is a Switzerland-based global healthcare leader and among the world’s largest pharmaceutical companies. Established in 1996 through the merger of Ciba-Geigy and Sandoz, the company operates across the research, development, manufacturing, and commercialization of a wide portfolio of healthcare products, including innovative pharmaceuticals, generics, and biosimilars. Novartis also emphasizes sustainable healthcare by pursuing initiatives aimed at reducing environmental impact and expanding access to medicines, particularly by improving affordability and availability in low- and middle-income countries.

Product Description: Pelacarsen

Pelacarsen (TQJ230), also known as IONIS-APO(a)-LRx and AKCEA-APO(a)-LRx, is an investigational antisense therapy designed to reduce apolipoprotein(a) production in the liver, thereby lowering lipoprotein(a) [Lp(a)], a highly atherogenic and thrombogenic form of LDL. Elevated Lp(a) is an independent genetic risk factor for cardiovascular conditions such as coronary artery disease, heart attack, stroke, and peripheral arterial disease. Originally discovered by Ionis Pharmaceuticals Inc. and licensed to Novartis International AG in 2019, pelacarsen is currently in Phase III clinical development for hyperlipoproteinaemia and atherosclerosis.

2. Company Overview: PharmaMar Group

PharmaMar Group is a Spain-based biopharmaceutical company focused on the discovery and development of innovative therapies, particularly in oncology. Headquartered in Madrid, the company is recognized for its marine-derived drug discovery platform, which explores bioactive compounds from ocean organisms to develop novel anticancer agents. PharmaMar also has activities in RNA-based therapeutics through its subsidiary Sylentis. With a presence in multiple international markets, the group emphasizes research-driven innovation, strategic collaborations, and expanding its global footprint in specialty therapeutics.

Product Description: Tivanisiran

Tivanisiran (SYL1001) is an investigational small interfering RNA (siRNA) therapy developed by Sylentis, a subsidiary of PharmaMar Group, for the treatment of dry eye disease. Formulated as preservative-free eye drops, it targets the TRPV1 receptor involved in ocular pain and inflammation, and works by silencing its expression to reduce symptoms such as discomfort and redness. Currently in Phase III for the treatment of Dry eyes clinical trials, it represents a novel approach to managing this multifactorial condition.

3. Company Overview: Oncotelic

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company based in Agoura Hills, California, focused on developing novel therapies for cancer and rare diseases. The company leverages RNA-based therapeutics and immuno-oncology strategies to target hard-to-treat tumors and fibrotic conditions, with key programs in glioblastoma, melanoma, and idiopathic pulmonary fibrosis. By integrating expertise in TGF-? inhibition and oligonucleotide technologies, along with strategic collaborations, Oncotelic aims to advance precision therapies addressing significant unmet medical needs.

Product Description: OT-101

OT-101 (trabedersen) is a novel antisense oligodeoxynucleotide therapy developed by Oncotelic Therapeutics for the treatment of multiple TGF-?2–overexpressing cancers, including pancreatic, colorectal, prostate, renal cell carcinoma, malignant melanoma, and high-grade glioma. It is an 18-mer phosphorothioate oligonucleotide designed to bind specifically to TGF-?2 mRNA, thereby inhibiting its expression. Since elevated TGF-? levels suppress the body’s innate immune response against tumors, OT-101 works by reversing this immunosuppressive effect, enabling immune-mediated recognition and elimination of cancer cells. The company had completed Phase II for pancreatic cancer and melanoma, and Phase II in glioblastoma with robust efficacy and safety. Currently therapy is being evaluated in Phase III clinical trial for multiple indications

4. Company Overview: Wave Life Sciences

Wave Life Sciences is a biotechnology company dedicated to advancing RNA-based medicines to transform human health. Its proprietary PRISM® platform integrates multiple modalities, innovative chemistry, and deep genetic insights to develop therapies targeting both rare and common diseases. The company leverages a broad toolkit, including RNA editing, splicing, RNA interference, and antisense approaches, to design precise and durable treatments aligned with disease biology. Wave’s diversified pipeline spans clinical programs in Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency, and Huntington’s disease, alongside a preclinical program in obesity, reflecting its focus on expanding the potential of RNA therapeutics.

Product Description: WVE-N531

WVE-N531 is an investigational exon-skipping oligonucleotide developed by Wave Life Sciences as a disease-modifying therapy for boys with Duchenne muscular dystrophy amenable to exon 53 skipping. Engineered using advanced oligonucleotide chemistry, including PN backbone modifications, it is designed to enhance therapeutic efficacy and stability. The candidate has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the US Food and Drug Administration. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Myotonic dystrophy.

Oligonucleotides Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: Oligonucleotides Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• Oligonucleotides Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Oligonucleotides Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Oligonucleotides Report Assessment (Dashboard Available with Site-license)

• Clinical Trial Analysis
• Clinical Trial Design Analysis
• Sponsor and Geographical Analysis

• Oligonucleotides Clinical Trial Analysis

The report comprises of comparative assessment of clinical trial analysis (by status, development stage, therapy area, enrolled participants by age, study completion year, end point status).

• Oligonucleotides Clinical Trial Design Analysis

The report comprises of comparative assessment of clinical trial design analysis (by allocation, interventional model, enrolled participants by status, masking).

• Sponsor and Geographical Analysis

The report comprises of comparative assessment of sponsor and geographical analysis (by top sponsors, developmental stage, clinical trials sponsored by countries, therapies by countries).

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Oligonucleotides drugs?
• How many Oligonucleotides drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oligonucleotides?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Oligonucleotides therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oligonucleotides and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

?

Key Players

• Novartis
• Astellas
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• PharMar Group
• Avidity Biosciences
• Amgen
• GSK
• Laboratoires Thea
• Stoke Therapeutics
• Arrowhead Pharmaceuticals / Visirna Therapeutics
• F. Hoffmann-La Roche Ltd
• Oncotelic
• Hanugen Therapeutics
• WaVe life Sciences
• Suzhou Sanegene Bio Inc.
• Biogen
• OAk Hill Bio
• Ono Pharma
• Rona Therapeutics
• Anges
• AstraZeneca
• Arrowhead Pharmaceuticals / GSK
• NS Pharma
• PepGen Inc
• Argo Biopharma
• Splisense
• Microbio
• Hangzhou Hygieia Pharmaceuticals Co., Ltd.
• CAGE Bio/ TAGCyx
• Causeway Therapeutics
• APTARION Biotech AG
• Ribomic
• Bio-Path Holdings
• Tangram Therapeutics
• Sirnaomics
• Judo Bio
• EMPIRICO INC
• Phio Pharmaceuticals
• Voyager Therapeutics
• AcuraStem
• QurAlis Corporation

Key Products

• LEQVIO
• IZERVAY
• AMVUTTRA
• TEGSEDI
• Tivanisiran
• Del-brax
• Olpasiran
• GSK3228836
• Sepofarsen
• STK-001
• Zodasiran
• Sefaxersen
• Trabedersen
• Research Program: Duchenne Muscular Dystrophy Exon Skipping
• WVE-N531
• SGB-9768
• BIIB080
• Rugonersen
• Sapablursen
• RN0361
• NF-?B Decoy Oligonucleotide
• ALXN2030
• GSK4532990
• Brogidirsen
• PGN-EDODM1
• BW-01
• SLP84
• SNS812
• Kylo-11
• TAGX-0003
• TenoMiR
• AON-D21
• RBM-007
• BP1003
• TGM-312
• RV-1730
• Research programme: oligonucleotide therapeutics
• EMP-CNS
• PH-894
• VY1706
• Research Program: UNC13A
• QRL-204